Recent results have indicated that the genetic variation at the CCL11 locus is an important determinant of serum total IgE levels among patients with asthma[46] and it is reasonable to suggest that CCL11 genotype may influence the response to medications that exert their effect via IgE receptors (e.g., Omalizumab). The gene discussed is CCL11; the disease is asthma.